Alps Group Inc 的盈利品質評分為 /。該評分基於盈利能力、增長、現金生成與資本分配以及槓桿四個維度。
Alps Group Inc 何時發布財報?
Alps Group Inc 的下一份財報預計在 2026-06-15 發布
Alps Group Inc 的預期收益是多少?
根據華爾街分析師的預測,Alps Group Inc 的預期收益為 $
Alps Group Inc 是否超出收益預期?
Alps Group Inc 最近的收益為 $, 預期。
關鍵數據
前收市價
$3.35
開盤價
$4.2
當日範圍
$3.05 - $4.2
52週區間
$0.5622 - $15
交易量
450
平均成交量
297.3K
股息收益率
--
每股盈餘 (TTM)
-0.51
市值
$525.9M
什麼是 GLLIU?
Alps Group, Inc. operates as a biotechnology company that integrates research and development, medical services, and wellness solutions. The company is headquartered in Kuala Lumpur, Wilayah Persekutuan. The company went IPO on 2025-10-31. The firm has cultivated a diverse pipeline covering various biotechnology research areas. This includes initiatives focused on MyImmune (NK cells), CAR-T cells, COVID-19 mRNA vaccine, diabetes therapeutics, and advancements in stem cell technologies such as induced Pluripotent Stem Cells (iPSCs) and messenger ribonucleic acid (mRNA) platform technology. The firm provides aesthetic treatments, cosmetic procedures, general healthcare and wellness services. The Company’s aesthetic services and cosmetic surgery services include non-surgical aesthetic services and surgical aesthetic services. The company operates a molecular laboratory and a cGMP cell and gene therapy research and cultivation laboratory.